Compare BIIB & ODFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIIB | ODFL |
|---|---|---|
| Founded | 1978 | 1934 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trucking Freight/Courier Services |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.5B | 36.0B |
| IPO Year | 1996 | 1996 |
| Metric | BIIB | ODFL |
|---|---|---|
| Price | $249.28 | $175.12 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 36 | 24 |
| Target Price | ★ $268.26 | $213.48 |
| AVG Volume (30 Days) | 1.1M | ★ 1.9M |
| Earning Date | 10-28-2026 | 10-28-2026 |
| Dividend Yield | N/A | ★ 0.68% |
| EPS Growth | N/A | ★ N/A |
| EPS | 2.66 | ★ 4.47 |
| Revenue | ★ $9,890,600,000.00 | $5,496,389,000.00 |
| Revenue This Year | $6.92 | $9.76 |
| Revenue Next Year | $1.91 | $8.31 |
| P/E Ratio | $94.29 | ★ $38.45 |
| Revenue Growth | ★ 2.22 | N/A |
| 52 Week Low | $160.36 | $126.01 |
| 52 Week High | $261.00 | $252.03 |
| Indicator | BIIB | ODFL |
|---|---|---|
| Relative Strength Index (RSI) | 54.04 | 48.58 |
| Support Level | $240.00 | $166.63 |
| Resistance Level | $259.89 | $180.18 |
| Average True Range (ATR) | 7.29 | 5.42 |
| MACD | -1.09 | 0.37 |
| Stochastic Oscillator | 43.79 | 56.74 |
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Old Dominion Freight Line is the second-largest less-than-truckload carrier in the United States (following FedEx Freight), with roughly 260 service centers and 11,000-plus tractors. It is one of the most disciplined and efficient providers in the trucking industry, and its profitability and capital returns are well above those of its peers. Strategic initiatives focus on increasing network density through market-share gains and on maintaining industry-leading service (including ultralow cargo claims) through steadfast infrastructure investment.